Breast Cancer Research and Treatment **37**: 303-304, 1996.
© 1996 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 37

Alberola V 209
Albitar M 179
Allt WEC 11
Arredondo MA 229
Attikiouzel Y 135

Balu-Maestro C 115
Barbareschi M 123
Barth NM 277
Bartow SA 243
Beale FA 11
Belloch V 209
Bertolli J 49
Bevilacqua P 123
Blumenson LE 229
Bonoldi E 123
Boracchi P 123
Boyd MT 243
Brazzale A 267
Brooks SC 253
Bruneton J-N 115
Bueso-Ramos CE 179
Bulbrook RD 11
Bush RS 11

Caldani C 77
Cambon P 115
Canbolat O 189
Cao Y 197
Capitanio G 267
Caroti C 93
Catozzi L 267
Çetin R 189
Chang K-J 291,299
Chang M-F 291
Chen K-M 291,299
Chevillard S 57
Choong PL 135
Christman JK 253
Chu J-S 291,299
Cibrián R 209
Ciocca DR 217
Clark RM 11

Dalla Palma P 123
Davis PL 1
Dawkins HJS 135
Dawson PJ 65
De Angelis RL 217
DeLeon C 277
Demirci S 189
deSilva CJS 135
Dillman RO 277
Dittadi R 267
Durak I 189

Earashi M 29
Edge SB 229

Fanelli MA 217
Fitzpatrick PJ 11

Gago FE 217
Gallo L 93
Ganott MA 1
García-Conde J 209
Gardini G 267
Gasparini G 123
Gelli MC 267
Gimotty PA 65
Gion M 267
Giovannini G 267
Glaros D 161
Glassman A 179
Granon C 115
Griffiths K 169

Haerslev T 101
Haidar MA 179
Haile RW 49
Harris KB 1
Harvey JM 135
Hatzikonstantinou I 161
Hawkins NV 11
Hayward JL 11
Hildebrandt RH 243
Hoff M 39
Huang C-S 291
Hume P 169
Hussein M 39

Inaji H 89

Jacobsen GK 101
Jarque F 209
Jenkin RDT 11

Kaija H 237
Kalef-Ezra JA 161
Karantanas A 161
Kavutcu M 189
Klementaviciene J 1
Klouvas G 161
Koyama H 89

Lahlou B 77
Lee W-J 291,299
Leroyer A 57
Lluch A 209

Magdelenat H 57
Malagutti R 267
Mammoliti S 93
Manshouri T 179
Matti H 237
McArdle C 169
McCarty KS Jr 1
McCown P 179
Meakin JW 11
Menegon A 267
Merlini L 93
Morrelli L 277
Mosseri V 57
Motomura K 89
Mourou M-Y 115

Nayak SK 277
Noguchi M 29
Noguchi S 89

O'Connor A 277
Ordonez N 179
Öztürk S 189

Paganini-Hill A 49
Paine TJ 65
Panzarella T 11
Papadimitriou J 135
Parkhouse W 21
Pauley RJ 65
Pauson AW 169
Pavlidis N 161
Pellizola D 267
Penetrante RB 229
Pierga J-Y 57
Piffanelli A 267
Pilat MJ 253
Pringle JF 11

Raffaelli C 115
Rider WD 11
Robbins P 135
Rostagno P 77

Siemiatycki J 49
Simon MS 39
Simpson HW 169
Smith D 39
Sneige N 179
Staiger ML 1
Stano M 39
Sterrett GF 135
Stewart CC 229
Stomper PC 229

Tanaka M 29
Tapani H 237
Tello O 217
Thompson WD 49
Tobon H 1
Turkes A 169

Ursin G 49

Vargas-Roig LM 217
Verderio P 123

Viehl P 57
Vizcarra E 209

Wang PP 197
Whittal K 21
Witte JS 49
Wolman SR 65

Yang Y 179
Ying S-Y 151

Zedeler K 101
Zhang Z 151

Breast Cancer Research and Treatment **36**: 305-308, 1996.
© 1996 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 37

activin
inhibin, activin, and activin receptor II in MCF-7 cells 151-160
adenosine deaminase
increased with 5'-nucleotidase in breast cancer 189-193
adjuvant therapy
ovarian irradiation plus prednisone 11-19
alcohol
as a risk factor in premenopausal bilateral breast cancer 49-56
animal models
NMU rat mammary tumors, effects of exercise 21-27
antiestrogens
see tamoxifen
atypia
no differences in mammographically dense or fatty breasts 229-236
autologous stem cell rescue
and high-dose chemotherapy — modifications and clinical outcomes 277-289
axillary lymph nodes
see nodal status

benign breast disease
abnormalities in breast luteal heat cycle 169-178
no differences in mammographically dense or fatty breasts 229-236
bilateral early-onset breast cancer
reproductive and other risk factors 49-56
bone marrow transplant
and high-dose chemotherapy — clinical outcomes 277-289
bone minerals
no effect of tamoxifen on composition 161-167
breast cancer incidence
trends over 59 years in Saskatchewan 197-207
breast development
estrogen receptor expression during 243-251
breast luteal heat cycle
abnormalities in benign disease and cancer-associated breasts 169-178

CA 15.3
vs. CEA, TPA as breast cancer serum markers 209-216
carcinoembryonic antigen (CEA)
vs. CA 15.3, TPA as breast cancer serum markers 209-216
chemotherapy
Phase II study of mitoxantrone, 5-FU, and levo-leucovorin in elderly patients 93-96
chemotherapy, high-dose
with autologous stem cell rescue — modifications and clinical outcomes 277-289
clinical management
costs of surveillance after primary treatment 39-47
color Doppler sonography
and breast cancer vascularity 291-298
sensitive detection of occult breast lesions 299-302
cost analysis
surveillance after primary treatment 39-47
use of resources over 5 years from diagnosis, by breast cancer stage 237-241
cyclooxygenase
inhibitors and growth of MDA-MB-231 cells 29-37

DCIS
see ductal carcinoma in situ
DNA turnover enzymes
increased adenosine deaminase, 5'-nucleotidase in breast cancer 189-193
ductal carcinoma in situ (DCIS)
inverse distribution of ErbB-2 protein and pS2 by sub-type 89-92

eicosanoids
and MDA-MB-231 cell growth 29-37
elderly patients
Phase II study of mitoxantrone, 5-FU, and levo-leucovorin 93-96
endocrine therapy
adjuvant ovarian irradiation plus prednisone 11-19

epidemiology
breast cancer incidence trends over 59 years in Saskatchewan 197-207
erbB-2 oncogene
amplification, overexpression, and early recurrence 65-76
ErbB-2 protein
concordance of four assay methods 267-276
inverse distribution of ErbB-2 protein and pS2 in DCIS by sub-type 89-92
estrogen receptor
association with proliferating (by PCNA, AgNORs) breast cancer cells 217-227
effects of transfection into MCF-10A cells — insufficient to transform 253-266
expression during human breast development and menstrual cycles 243-251
image analysis of cell cycle expression in MCF-7 cells 77-87
tamoxifen effects on expression during cell cycle 77-87
exercise
effects on mammary development, NMU tumors (rat model) 21-27

familial breast cancer
reproductive and other risk factors in early bilateral breast cancer 49-56
fibrocystic change
elevated estrogen receptor expression 243-251
5-fluorouracil
Phase II study of mitoxantrone, 5-FU, and levo-leucovorin in elderly patients 93-96

gadolinium contrast agent
in MRI determination of tumor size 1-9
growth factors
inhibin, activin, and activin receptor II in MCF-7 cells 151-160

HER-2/*neu*
see erbB-2
histologic grading
vs. Ki-S1, Ki-67, PgR, etc. in prognosis 123-133
hospital services
5 year cost by stage of breast cancer at diagnosis 237-241

image cytometry
cell cycle expression of steroid receptors in MCF-7 cells 77-87
imaging
indications for hepatic ultrasonography 115-121
MRI vs. ultrasound, mammography, in size determination 1-9
see also color Doppler sonography 291-298
inhibin
and activin, activin receptor II, in MCF-7 cells 151-160
int2 amplification
and high recurrence risk 65-76

Ki-67 growth fraction
and PCNA by IHC in prognosis 101-113
vs. Ki-S1 in prognosis 123-133
and prognosis 57-64
Ki-S1
as a proliferation marker — lack of prognostic significance 123-133

leukotriene B
and MDA-MB-231 cell growth 29-37
levo-leucovorin
Phase II study of mitoxantrone, 5-FU, and levo-leucovorin in elderly patients 93-96
lipoxygenase
inhibitors and growth of MDA-MB-231 cells 29-37
liver metastases
indications for hepatic ultrasonography 115-121
logistic regression
vs. maximum entropy estimation in predicting nodal status 135-149
luteal heat cycle of the breast
abnormalities in benign disease and cancer-associated breasts 169-178

magnetic resonance imaging (MRI)
vs. ultrasound, mammography, in size determination 1-9
mammary gland development
effects of exercise during adolescence (rat model) 21-27
mammographic parenchymal patterns
normal dense or fatty breasts — no differences in atypia or S-phase 229-236

mammography
vs. MRI, ultrasound, in size determination 1-9
markers
serum CA 15.3 vs CEA, TPA 209-216
maximum entropy estimation
vs. logistic regression in predicting nodal status 135-149
MCF-7 cells
inhibin, activin, and activin receptor II 151-160
tamoxifen effect on cell cycle expression of steroid receptors 77-87
MCF-10A cells
effects of transfected estrogen receptor 253-266
MDA-MB-231 cells
effects of lipoxygenase and cyclooxygenase inhibitors, eicosanoid levels 29-37
MDM-2 oncoprotein
overexpression without amplification in many breast cancers 179-188
mitoxantrone
Phase II study of mitoxantrone, 5-FU, and levo-leucovorin in elderly patients 93-96

NMU-induced rat mammary tumors
effects of exercise during adolescence 21-27
nodal status
prediction from tumor factors by maximum entropy estimation method 135-149
nucleolar organizer regions
silver-stained (AgNORs) — association with ER and PgR 217-227
5'-nucleotidase
increased with adenosine deaminase in breast cancer 189-193

oncoproteins
overexpression of p53 inhibitor MDM-2 in many breast cancers 179-188
ovarian irradiation
in adjuvant therapy 11-19

p53
overexpression of inhibitor MDM-2 in many breast cancers 179-188
PCNA
and Ki-67 by IHC in prognosis 101-113
proliferating cells, association with ER and PgR 217-227
prednisone
with ovarian irradiation in adjuvant therapy 11-19
premenopausal bilateral breast cancer
reproductive and other risk factors 49-56
progesterone receptor
association with proliferating (by PCNA, AgNORs) breast cancer cells 217-227
image analysis of cell cycle expression in MCF-7 cells 77-87
with Ki-67, PCNA, in prognosis 101-113
prognostic factors
erbB-2 amplification, overexpression 65-76
ErbB-2 protein — concordance of four assay methods 267-276
int2 amplification 65-76
Ki-67 and PCNA vs. PgR and standard factors in multivariate analysis 101-113
Ki-67 growth fraction by immunohistochemistry 57-64
Ki-S1 vs Ki-67, PgR, grading, etc. 123-133
nodal status prediction from tumor factors 135-149
proliferating cell nuclear antigen
see PCNA
proliferation markers
Ki-S1 vs. Ki-67 123-133
proliferation rate
by PCNA, AgNORs — association with ER, PgR 217-227
Ki-67 and PCNA by IHC in prognosis 101-113
Ki-67 growth fraction and prognosis 57-64
prostaglandin E
and MDA-MB-231 cell growth 29-37
pS2 protein
inverse distribution of ErbB-2 protein and pS2 in DCIS by sub-type 89-92

reproductive risk factors
in premenopausal bilateral breast cancer 49-56
risk factors
reproductive and other risk factors in early bilateral breast cancer 49-56

S-phase
no differences in mammographically dense or fatty breasts 229-236

serum markers
see markers
smoking
as a risk factor in premenopausal bilateral breast cancer 49-56
stage
and 5 year cost of health care resources 237-241
surveillance after primary treatment
costs and physician practice patterns 39-47

tamoxifen
and cell cycle expression of steroid receptors in MCF-7 cells 77-87
no effect on bone mineral elemental composition 161-167
TGFβ growth factor superfamily
inhibin, activin, and activin receptor II in MCF-7 cells 151-160
tissue polypeptide antigen (TPA)
vs. CA 15.3, CEA as breast cancer serum markers 209-216
tumor size
MRI vs. ultrasound, mammography 109

ultrasound
indications for hepatic ultrasonography 115-121
vs. MRI, mammography, in size determination 1-9
see also color Doppler sonography

vascularity
assessment by color Doppler sonography 291-298